Medication-related osteonecrosis of the jaw (MRONJ) is a severe complication of bisphosphonates (BPs) or other targeted agent therapies. MRONJ appears as exposed bone, pus, and swelling in the oral and maxillofacial regions. However, neither surgery nor conservative therapy can eliminate symptoms thoroughly. In addition to BPs, several antiresorptive and antiangiogenic agents, such as denosumab and bevacizumab, as well as targeted agents, such as sunitinib and temsirolimus, can cause osteonecrosis of the jaw according to the literature. This review aims to summarize the research progress on these new drugs.
药物性颌骨坏死（MRONJ）是使用双膦酸盐类药物（BPs）或其他生物靶向药物而产生的一种严重不良反应，临床上以颌骨骨面裸露、流脓、面部肿胀等为特征，手术治疗或保守治疗均不能达到理想的效果。近年来，除了已经普遍使用的BPs外，国内外报道了许多可以导致颌骨坏死的新型药物，包括抑制骨吸收药物狄诺塞麦，抗血管生成药物贝伐单抗，以及其他生物靶向药物舒尼替尼、西罗莫司等。本文就这些导致颌骨坏死的新药研究进展作一综述。.
Keywords: bevacizumab; bisphosphonates; denosumab; osteonecrosis.